Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sight Sciences (NASDAQ:SGHT) executives, speaking at the Morgan Stanley Global Healthcare Conference, addressed current headwinds in the Minimally Invasive Glaucoma Surgery (MIGS) market, attributing them to recent LCD and payment changes. The company anticipates these pressures will normalize by Q4, projecting a return to growth for the broader MIGS market in 2026, driven by increasing patient demand for interventional glaucoma solutions. Despite the near-term challenges, Sight Sciences reported strong internal performance within the segment.

Analysis

At the Morgan Stanley Global Healthcare Conference, Sight Sciences (SGHT) management addressed the significant near-term headwinds impacting the Minimally Invasive Glaucoma Surgery (MIGS) market, which they attribute directly to recent LCD and payment changes. The CEO, Paul Badawi, projected that the negative impact of these changes will anniversary, or "lap," in the fourth quarter. Despite the current challenging environment, management remains optimistic, forecasting a return to growth for the overall MIGS market in 2026. This outlook is supported by the fundamental and growing demand for interventional glaucoma treatments, noted by continuing growth in patient visits. Furthermore, the company expressed confidence in its own commercial execution, stating it has performed well despite the adverse market conditions.

Key Decisions for Investors

• Investors should anticipate continued pressure on SGHT's performance and stock valuation through Q4, as the company navigates the ongoing reimbursement headwinds impacting the entire MIGS sector.
• The primary catalyst to monitor is the normalization of the market environment post-Q4, with the company's projection of a return to market growth in 2026 serving as a key element of the long-term investment thesis.
• It is critical to scrutinize Sight Sciences' upcoming quarterly earnings to validate management's claims of strong commercial execution and potential market share gains during this industry downturn.